Breaking News

Ginkgo Bioworks Awarded mAbs BARDA Project  

To develop monoclonal antibody biomanufacturing innovations and produce an anti-filovirus medical countermeasure.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ginkgo Bioworks

Ginkgo Bioworks has been awarded a contract through the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) to protect against and treat infection by filoviruses such as Ebola (EBOV) and Sudan Viruses (SUDV). The project has a total contract value of up to $22.2 million and seeks ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters